Verastem (VSTM) Competitors $9.29 +0.39 (+4.38%) Closing price 04:00 PM EasternExtended Trading$9.17 -0.12 (-1.29%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VSTM vs. BCRX, CLDX, NVAX, INVA, DVAX, MNKD, OPK, GERN, RIGL, and ZBIOShould you be buying Verastem stock or one of its competitors? The main competitors of Verastem include BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), Rigel Pharmaceuticals (RIGL), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. Verastem vs. Its Competitors BioCryst Pharmaceuticals Celldex Therapeutics Novavax Innoviva Dynavax Technologies MannKind OPKO Health Geron Rigel Pharmaceuticals Zenas BioPharma Verastem (NASDAQ:VSTM) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Do analysts recommend VSTM or BCRX? Verastem currently has a consensus target price of $13.29, suggesting a potential upside of 43.01%. BioCryst Pharmaceuticals has a consensus target price of $16.70, suggesting a potential upside of 96.01%. Given BioCryst Pharmaceuticals' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Verastem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Is VSTM or BCRX more profitable? Verastem has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -6.41%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Verastem's return on equity.Company Net Margins Return on Equity Return on Assets VerastemN/A -2,003.62% -119.85% BioCryst Pharmaceuticals -6.41%N/A -1.78% Which has more risk & volatility, VSTM or BCRX? Verastem has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Does the media prefer VSTM or BCRX? In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Verastem. MarketBeat recorded 7 mentions for BioCryst Pharmaceuticals and 6 mentions for Verastem. BioCryst Pharmaceuticals' average media sentiment score of 1.48 beat Verastem's score of 0.77 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in VSTM or BCRX? 88.4% of Verastem shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 2.1% of Verastem shares are held by company insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation & earnings, VSTM or BCRX? BioCryst Pharmaceuticals has higher revenue and earnings than Verastem. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVerastem$2.14M267.55-$130.64M-$3.28-2.83BioCryst Pharmaceuticals$450.71M3.97-$88.88M-$0.18-47.33 SummaryBioCryst Pharmaceuticals beats Verastem on 11 of the 17 factors compared between the two stocks. Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VSTM vs. The Competition Export to ExcelMetricVerastemMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$571.75M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E Ratio-2.8321.2230.8326.39Price / Sales267.55206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book15.758.0710.106.62Net Income-$130.64M-$54.08M$3.26B$265.42M7 Day Performance11.66%3.94%3.90%3.58%1 Month Performance51.30%3.02%3.73%0.46%1 Year Performance276.11%6.84%37.68%19.41% Verastem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VSTMVerastem3.147 of 5 stars$9.29+4.4%$13.29+43.0%+241.0%$571.75M$2.14M-2.8350Analyst UpgradeBCRXBioCryst Pharmaceuticals4.1499 of 5 stars$8.38+0.1%$16.70+99.3%+4.3%$1.76B$450.71M-46.55530Positive NewsCLDXCelldex Therapeutics1.7239 of 5 stars$24.48-4.0%$51.75+111.4%-42.3%$1.69B$7.02M-8.13150News CoverageNVAXNovavax4.5429 of 5 stars$9.71+1.4%$15.86+63.3%-34.8%$1.56B$682.16M4.261,990INVAInnoviva4.4949 of 5 stars$20.78-0.7%$42.75+105.7%+5.2%$1.32B$358.71M67.03100News CoveragePositive NewsAnalyst DowngradeDVAXDynavax Technologies4.6953 of 5 stars$10.76-0.3%$24.33+126.1%-8.4%$1.27B$277.25M-23.39350MNKDMannKind3.2835 of 5 stars$3.81+2.1%$9.71+155.0%-24.3%$1.14B$285.50M34.64400Trending NewsAnalyst ForecastOPKOPKO Health4.433 of 5 stars$1.40+2.2%$2.75+96.4%-14.2%$1.09B$664.03M-5.602,997Positive NewsGERNGeron2.9594 of 5 stars$1.44-0.7%$4.19+190.8%-68.0%$925.12M$76.99M-11.08229Positive NewsRIGLRigel Pharmaceuticals1.7477 of 5 stars$40.07+1.4%$38.20-4.7%+209.4%$708.70M$179.28M7.41160ZBIOZenas BioPharma1.5187 of 5 stars$17.28+2.7%$36.67+112.2%N/A$708.29M$5M0.00N/AHigh Trading Volume Related Companies and Tools Related Companies BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Novavax Alternatives Innoviva Alternatives Dynavax Technologies Alternatives MannKind Alternatives OPKO Health Alternatives Geron Alternatives Rigel Pharmaceuticals Alternatives Zenas BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VSTM) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access